Oncology Newsfeed

FDA Grants Accelerated Approval to Adagrasib for KRAS G12C-Mutated NSCLC

On December 12, 2022, the U.S Food and Drug Administration (FDA) granted accelerated approval to adagrasib, a RAS GTPase family inhibitor, for adult patients with KRAS G12C—mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.

For more information read the FDA announcement.  

Posted 12/13/2022

FDA Grants Approval to Atezolizumab for Alveolar Soft Part Sarcoma

On December 9, 2022, the U.S Food and Drug Administration (FDA) approved atezolizumab for adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma.

For more information read the FDA announcement.

Posted 12/12/2022

FDA Approves a New Dosing Regimen for Asparaginase Erwinia Chrysanthemi

On November 18, 2022, the U.S Food and Drug Administration (FDA) approved a new Monday-Wednesday-Friday dosing regimen for asparaginase erwinia chrysanthemi (recombinant)-rywn. Under the new regimen, patients should receive 25 mg/m2 intramuscularly on Monday and Wednesday mornings, and 50 mg/m2 intramuscularly on Friday afternoon. 

For more information, read the FDA announcement.

Posted 11/21/2022

Roche Receives FDA Approval for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay

On November 14, 2022, the U.S Food and Drug Administration (FDA) approved the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the first immunohistochemistry companion diagnostic test to aid in identifying epithelial ovarian cancer patients who are eligible for targeted treatment with mirvetuximab soravtansine-gynx. 

For more information, read the Roche announcement.

Posted 11/16/2022

FDA Grants Accelerated Approval to Mirvetuximab Soravtansine-gynx

On November 14, 2022, the U.S Food and Drug Administration granted accelerated approval to mirvetuximab soravtansine-gynx for adult patients with folate receptor alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.

For more information, read the FDA announcement and the ImmunoGen announcement. 

Posted 11/15/22

FDA Approves Brentuximab Vedotin + Chemo for Pediatric Patients with Hodgkin’s Lymphoma

On November 10, 2022, the U.S Food and Drug Administration (FDA) approved brentuximab vedotin in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients 2 years of age and older with previously untreated high risk classical Hodgkin lymphoma. This is the first pediatric approval for brentuximab vedotin.

For more information, read the FDA announcement.

Posted 11/15/2022

FDA Approves Tremelimumab with Durvalumab + Chemotherapy for Metastatic NSCLC

On November 10, 2022, the U.S Food and Drug Administration (FDA) approved tremelimumab in combination with durvalumab and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor mutation or anaplastic lymphoma kinase genomic tumor aberrations.

For more information, read the FDA announcement.

Posted 11/15/2022

FDA Approves Cemiplimab + Chemotherapy for NSCLC

On November 8, 2022, the U.S Food and Drug Administration (FDA) approved cemiplimab-rwlc in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with no EGFR, ALK, or ROS1 aberrations.

For more information, read the FDA Announcement and the Regeneron press release.

Posted 11/9/2022

Calendar Year 2023 Medicare Physician Fee Schedule Released

The Centers for Medicare & Medicaid Services (CMS) has finalized changes in CMS’s annual Physician Fee Schedule (PFS) proposed rule to significantly expand access to behavioral health services and moves the health system closer to achieving equitable outcomes through high quality, affordable, person-centered care. These changes will ensure CMS continues to deliver on their goals of advancing health equity, driving accountable care, and protecting the sustainability of the Medicare program.

For more information, read the press release.

Posted 11/2/2022. 

Cost and Coordination of Care Head List of Concerns with Combination Anti-Cancer Therapy

Patients undergoing anti-cancer treatment that incorporates intravenous and oral agents may experience compound adverse effects and challenges related to treatment adherence. Through a national mixed-methods study, ACCC is assessing how care coordination may be improved for these patients. Read more from Oncology Nurse Advisor.

Posted 10/21/2022